{
    "id": 190,
    "entrez_name": "EGFR",
    "entrez_id": 1956,
    "name": "AMPLIFICATION",
    "description": "",
    "gene_id": 19,
    "type": "variant",
    "variant_types": [
        {
            "id": 123,
            "name": "transcript_amplification",
            "display_name": "Transcript Amplification",
            "so_id": "SO:0001889",
            "description": "A feature amplification of a region containing a transcript.",
            "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001889"
        }
    ],
    "civic_actionability_score": 133,
    "coordinates": {
        "chromosome": "7",
        "start": 55086794,
        "stop": 55279321,
        "reference_bases": null,
        "variant_bases": null,
        "representative_transcript": "ENST00000275493.2",
        "chromosome2": null,
        "start2": null,
        "stop2": null,
        "representative_transcript2": null,
        "ensembl_version": 75,
        "reference_build": "GRCh37"
    },
    "evidence_items": {
        "id": 7785,
        "name": "EID7785",
        "description": "Preclinical experiments with 27 GBM patient-derived cell lines showed selective sensitivity to the PARP inhibitor talazoparib in EGFR amplified samples relative to EGFR wild-type samples (p<0.0001). Functional assays showed that EGFR signaling was required for EGFR-mediated cellular inhibition by talazoparib, and that ROS levels, DNA repair capacity, and PARP trapping are associated with response in EGFR amplified cells. Talazoparib treatment also suppressed tumour growth and induced DNA damage and apoptosis in vivo for two EGFR amplified models, but not for two non-amplified models.",
        "disease": {
            "id": 19,
            "name": "Glioblastoma Multiforme",
            "display_name": "Glioblastoma Multiforme",
            "doid": "3068",
            "url": "http://www.disease-ontology.org/?id=DOID:3068"
        },
        "drugs": [
            {
                "id": 168,
                "name": "Talazoparib",
                "ncit_id": "C95733",
                "aliases": [
                    "BMN-673",
                    "BMN 673"
                ]
            }
        ],
        "rating": 4,
        "evidence_level": "D",
        "evidence_type": "Predictive",
        "clinical_significance": "Sensitivity/Response",
        "evidence_direction": "Supports",
        "variant_origin": "Somatic",
        "drug_interaction_type": null,
        "status": "submitted",
        "type": "evidence",
        "source": {
            "id": 3112,
            "name": "EGFR amplification induces increased DNA damage response and renders selective sensitivity to Talazoparib (PARP inhibitor) in glioblastoma.",
            "citation": "Wu et al., 2019, Clin. Cancer Res.",
            "citation_id": "31852834",
            "source_type": "PubMed",
            "asco_abstract_id": null,
            "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/31852834",
            "open_access": null,
            "pmc_id": null,
            "publication_date": {
                "year": 2019,
                "month": 12,
                "day": 18
            },
            "journal": "Clin. Cancer Res.",
            "full_journal_title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
            "status": "partially curated",
            "is_review": false,
            "clinical_trials": []
        },
        "variant_id": 190,
        "phenotypes": []
    },
    "variant_groups": [],
    "assertions": [],
    "variant_aliases": [],
    "hgvs_expressions": [],
    "clinvar_entries": [
        "N/A"
    ],
    "allele_registry_id": null
}